Global med tech company Orthofix Medical Inc. has announced the expansion of its partnership with international nonprofit MTF Biologics. The updated agreement will extend marketing rights to Orthofix’s Trinity™ allograft line through 2032. The collaboration will also include an additional expansion agreement for Orthofix to develop and market Legacy™ demineralized bone matrix (DBM). The product is projected to be available by the third quarter of 2022. Legacy DBM is an addition to Orthofix’s current FiberFuse demineralized bone line, which consists of FiberFuse Advanced and FiberFuse Strip, both also by MTF Biologics.
Orthofix Expands Partnership With MTF Biologics
2 min read Premium comments
Secondary#orthofixmedical#mtfbiologics
“MTF Biologics is pleased to strengthen our exclusive partnership with Orthofix to continue our joint investments in innovative solutions, and the provision of Trinity Elite™ and Trinity Evolution™ allografts,” said MTF Biologics President and CEO Joe Yaccarino. “This agreement aligns with MTF Biologics’ mission of honoring donor families by serving patients who are in need of grafts and innovative allograft solutions to aid them on their road to recovery.”
Orthofix offers orthopedic surgeons a portfolio of spine and surgical solutions that also includes Opus BA bioactive bone graft, Opus™ Mg Set bone void filler, the O-Genesis™ graft delivery system, and the Collage™ osteoconductive scaffold. With headquarters in Lewisville, Texas, the global medical device company has a mission to deliver innovative, high quality solutions while partnering with medical providers to improve patient mobility. Orthofix’s products are distributed in over 60 countries.
Edison, New Jersey-based MTF Biologics is an international nonprofit dedicated to saving lives via donated gifts. The nonprofit provides service, resources, and expertise to both donors and recipients of tissue and organ transplants. This work is done through a special division of MTF Biologics, the International Institute for the Advancement of Medicine (IIAM). IIAM supports the donation of non-transplantable organs through gifting them to the medical research community. The Statline division of MTF Biologics specializes in communications and technology expertise related to tissue and organ donation, and its sister organization, Deutsches Institute for Zell-und Gewebeersatz (The German Institute for Cell and Tissue Transplantation) brings such services to an international level.
“Together Orthofix and MTF Biologics have a long history of bringing advanced biologic solutions to the market, with more than 350,000 patients receiving their Trinity allografts,” said Kevin Kenny, Orthofix President of Global Spine. “This agreement solidifies our partnership with MTF Biologics as the sole provider of MTF allograft offerings. The addition of the Legacy demineralized bone line will expand our biologic portfolio, increasing the options available and offering a value solution for our customers and their patients.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.